Life-style modification in peripheral arterial disease

European Journal of Vascular and Endovascular Surgery

Volumn 29, Issue 1, 2005, Pages 2-9

  Khan, S ^a   Cleanthis, M ^b   Smout, J ^a   Flather, M ^c   Stansby, Gerard ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Diet; Exercise; Obesity; Peripheral arterial disease; Smoking; Weight loss

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTILIPEMIC AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; ATORVASTATIN; BIOCHEMICAL MARKER; DOPAMINE UPTAKE INHIBITOR; FISH OIL; FOLIC ACID; GAMMA LINOLENIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; NICOTINE; NORADRENALIN UPTAKE INHIBITOR; OLIVE OIL; SEROTONIN UPTAKE INHIBITOR;

ALCOHOL CONSUMPTION; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DIETARY FIBER; HUMAN; HYPERHOMOCYSTEINEMIA; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LIFESTYLE; LOW FAT DIET; MEDICAL LITERATURE; MEDITERRANEAN DIET; META ANALYSIS; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING CESSATION; SODIUM RESTRICTION; TOBACCO DEPENDENCE; WALKING;

ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; DIET THERAPY; EXERCISE; HEALTH BEHAVIOR; HUMANS; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS; RISK REDUCTION BEHAVIOR; SMOKING CESSATION;

EID: 10244230997     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2004.09.020     Document Type: Review

References (120)

1. K. Cassar R. Coull P. Bachoo E. Macaulay J. Brittenden Management of secondary risk factors in patients with intermittent claudication Eur J Vasc Endovasc Surg 26 2003 262-266
2. M.M. McDermott S. Mehta H. Ahn P. Greenland Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease J Gen Intern Med 12 1997 209-215
3. F.N. Brand R.D. Abbott W.B. Kannel Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham study Diabetes 38 1989 504-509
4. R. Collins J. Armitage S. Parish P. Sleigh R. Peto MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial Lancet 361 2003 2005-2016
5. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003;26:1-16.
6. P. Robless D.P. Mikhailidis G. Stansby Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease Br J Surg 88 2001 787-800
7. G.C. Leng A.J. Lee F.G. Fowkes et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease Clin Nutr 17 1998 265-271
8. M.E. Tornwall J. Virtamo J.K. Haukka A. Aro D. Albanes J.K. Huttunen Prospective study of diet, lifestyle, and intermittent claudication in male smokers Am J Epidemiol 151 2000 892-901
9. W.T. Meijer D.E. Grobbee M.G. Hunink A. Hofman A.W. Hoes Determinants of peripheral arterial disease in the elderly: The Rotterdam study Arch Intern Med 160 2000 2934-2938
10. W.B. Kannel D.L. McGee Update on some epidemiologic features of intermittent claudication: The Framingham study J Am Geriatr Soc 33 1985 13-18
11. F.G. Fowkes E. Housley R.A. Riemersma et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh artery study Am J Epidemiol 135 1992 331-340
12. H. Drexel J. Steurer J. Muntwyler et al. Predictors of the presence and extent of peripheral arterial occlusive disease Circulation 94 Suppl 9 1996 II199-II205
13. D. Bainton P. Sweetnam I. Baker P. Elwood Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study Br Heart J 72 1994 128-132
14. S.J. Bowlin J.H. Medalie S.A. Flocke S.J. Zyzanski U. Goldbourt Epidemiology of intermittent claudication in middle-aged men Am J Epidemiol 140 1994 418-430
15. T. Jonason R. Bergstrom Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality Acta Med Scand 221 1987 253-260
16. I.O. Ingolfsson G. Sigurdsson H. Sigvaldason G. Thorgeirsson N. Sigfusson A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: A strong relationship to smoking and serum cholesterol-the Reykjavik study J Clin Epidemiol 47 1994 1237-1243
17. G.R. Dagenais S. Maurice N.M. Robitaille S. Gingras P.J. Lupien Intermittent claudication in Quebec men from 1974-1986: The Quebec cardiovascular study Clin Invest Med 14 1991 93-100
18. J.T. Powell R.J. Edwards P.C. Worrell P.J. Franks R.M. Greenhalgh N.R. Poulter Risk factors associated with the development of peripheral arterial disease in smokers: A case-control study Atherosclerosis 129 1997 41-48
19. J.D. Hooi A.D. Kester H.E. Stoffers M.M. Overdijk J.W. van Ree J.A. Knottnerus Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: A longitudinal study Am J Epidemiol 153 2001 666-672
20. J.L. Cronenwett K.G. Warner G.B. Zelenock et al. Intermittent claudication. Current results of nonoperative management Arch Surg 119 1984 430-436
21. J.A. Dormandy R.B. Rutherford Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Concensus (TASC) J Vasc Surg 2 1 Pt 2 2000 S1-S296
22. J.L. Juergens N.W. Barker E.A. Hines Jr Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors Circulation 21 1960 188-195
23. W.B. Kannel J.J. Skinner Jr M.J. Schwartz D. Shurtleff Intermittent claudication. Incidence in the Framingham study Circulation 41 1970 875-883
24. S.W. Cheng A.C. Ting H. Lau J. Wong Survival in patients with chronic lower extremity ischemia: A risk factor analysis Ann Vasc Surg 14 2000 158-165
25. A.T. Hirsch D. Treat-Jacobson H.A. Lando D.K. Hatsukami The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease Vasc Med 2 1997 243-251
26. S. Wiseman J. Powell R. Greenhalgh et al. The influence of smoking and plasma factors on prosthetic graft patency Eur J Vasc Surg 4 1990 57-61
27. S. Wiseman G. Kenchington R. Dain et al. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts Br Med J 299 1989 643-646
28. M.E. Giswold G.J. Landry G.J. Sexton et al. Modifiable patient factors are associated with reverse vein graft occlusion in the era of duplex scan surveillance J Vasc Surg 37 2003 47-53
29. S.D. Hobbs A.W. Bradbury Smoking cessation strategies in patients with peripheral arterial disease: An evidence-based approach Eur J Vasc Endovasc Surg 26 2003 341-347
30. K.W. Faulkner A.K. House W.M. Castleden The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease Med J Aust 1 1983 217-219
31. J. Moxham Nicotine addiction Br Med J 320 2000 391-392
32. J.O. Prochaska C.C. DiClemente J.C. Norcross In search of how people change. Applications to addictive behaviors Am Psychol 47 1992 1102-1114
33. R.J. Bloom C.A. Stevick S. Lennon Patient perspectives on smoking and peripheral vascular disease. A veteran population survey Am Surg 56 1990 535-539
34. B. Karnath Smoking cessation Am J Med 112 2002 399-405
35. B. Fowler K. Jamrozik P. Norman Y. Allen E. Wilkinson Improving maximum walking distance in early peripheral arterial disease: Randomised controlled trial Aust J Physiother 48 2002 269-275
36. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2003;(2):CD000031.
37. J.J. Mahmarian L.A. Moye G.A. Nasser et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia J Am Coll Cardiol 30 1997 125-130
38. N.L. Benowitz S.G. Gourlay Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy J Am Coll Cardiol 29 1997 1422-1431
39. Working group for the study of transdermal nicotine in patients with coronary artery disease Nicotine replacement therapy for patients with coronary artery disease Arch Intern Med 154 1994 989-995
40. A.M. Joseph S.M. Norman L.H. Ferry et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease N Engl J Med 335 1996 1792-1798
41. H. McRobbie P. Hajek Nicotine replacement therapy in patients with cardiovascular disease: Guidelines for health professionals Addiction 96 2001 1547-1551
42. P. Hajek R. West Treating nicotine dependence: The case for specialist smokers' clinics Addiction 93 1998 637-640
43. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;(1):CD003041.
44. E. Housley G.C. Leng P.T. Donnan F.G. Fowkes Physical activity and risk of peripheral arterial disease in the general population: Edinburgh artery study J Epidemiol Community Health 47 1993 475-480
45. J.G. Regensteiner A. Gardner W.R. Hiatt Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: Status in 1997 Vasc Med 2 1997 147-155
46. T. Jonason I. Ringqvist A. Oman-Rydberg Home-training of patients with intermittent claudication Scand J Rehabil Med 13 1981 137-141
47. P.C. Clifford P.W. Davies J.A. Hayne R.N. Baird Intermittent claudication: Is a supervised exercise class worth while? Br Med J 280 1980 1503-1505
48. J.G. Regensteiner T.J. Meyer W.C. Krupski L.S. Cranford W.R. Hiatt Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease Angiology 48 1997 291-300
49. E. Mannarino L. Pasqualini M. Menna G. Maragoni U. Orlandi Effects of physical training on peripheral vascular disease: A controlled study Angiology 40 1989 5-10
50. K. Fujita H. Takahashi C. Miura et al. Walking and mortality in Japan: the Miyagi Cohort study J Epidemiol 14 Suppl 1 2004 S26-S32
51. M.F. Piepoli C. Davos D.P. Francis A.J. Coats Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) Br Med J 328 2004 189
52. D.R. Cheetham L. Burgess M. Ellis A. Williams R.M. Greenhalgh A.H. Davies Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomised trial Eur J Vasc Endovasc Surg 27 2004 17-23
53. Jolliffe JA, Rees , K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001;(1):CD001800.
54. E.G. Collins W. Edwin Langbein C. Orebaugh et al. Pole-Striding exercise and vitamin E for management of peripheral vascular disease Med Sci Sports Exerc 35 2003 384-393
55. R.D. Walker S. Nawaz C.H. Wilkinson J.M. Saxton A.G. Pockley R.F. Wood Influence of upper- and lower-limb exercise training on cardiovascular function and walking distances in patients with intermittent claudication J Vasc Surg 31 2000 662-669
56. O.A. Larsen N.A. Lassen Effect of daily muscular exercise in patients with intermittent claudication Lancet 2 1966 1093-1096
57. B. Ericsson K. Haeger S.E. Lindell Effect of physical training of intermittent claudication Angiology 21 1970 188-192
58. F. Lundgren A.G. Dahllof T. Schersten A.C. Bylund-Fellenius Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of different treatments and consequences on walking performance Clin Sci (Lond) 77 1989 485-493
59. F. Lundgren A.G. Dahllof K. Lundholm T. Schersten R. Volkmann Intermittent claudication-surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency Ann Surg 209 1989 346-355
60. E. Mannarino L. Pasqualini S. Innocente V. Scricciolo A. Rignanese G. Ciuffetti Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: Alone or combined? Angiology 42 1991 513-521
61. W.R. Hiatt E.E. Wolfel R.H. Meier J.G. Regensteiner Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response Circulation 90 1994 1866-1874
62. A.W. Gardner E.T. Poehlman Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis JAMA 274 1995 975-980
63. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;(2):CD000990.
64. A.W. Gardner L.I. Katzel J.D. Sorkin et al. Improved functional outcomes following exercise rehabilitation in patients with intermittent claudication J Gerontol A Biol Sci Med Sci 55 2000 M570-M577
65. A.W. Gardner L.A. Killewich Association between physical activity and endogenous fibrinolysis in peripheral arterial disease: A cross-sectional study Angiology 53 2002 367-374
66. J.G. Regensteiner J.F. Steiner W.R. Hiatt Exercise training improves functional status in patients with peripheral arterial disease J Vasc Surg 23 1996 104-115
67. L.R. Williams M.A. Ekers P.S. Collins J.F. Lee Vascular rehabilitation: benefits of a structured exercise/risk modification program J Vasc Surg 14 1991 320-326
68. R. de la Haye C. Diehm J. Blume et al. An epidemiologic study of the value and limits of physical therapy/exercise therapy in Fontaine stage II arterial occlusive disease Vasa Suppl 38 1992 1-40
69. A.W. Gardner L.I. Katzel J.D. Sorkin A.P. Goldberg Effects of long-term exercise rehabilitation on claudication distances in patients with peripheral arterial disease: A randomized controlled trial J Cardiopulm Rehabil 22 2002 192-198
70. A.M. Izquierdo-Porrera A.W. Gardner C.C. Powell L.I. Katzel Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease J Vasc Surg 31 2000 670-677
71. S. Rosfors S. Bygdeman B.B. Arnetz et al. Longterm neuroendocrine and metabolic effects of physical training in intermittent claudication Scand J Rehabil Med 21 1989 7-11
72. W.R. Hiatt A.T. Hirsch J.G. Regensteiner E.P. Brass Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular clinical trialists Circulation 92 1995 614-621
73. R.B. Singh G. Dubnov M.A. Niaz et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean diet heart study): A randomised single-blind trial Lancet 360 2002 1455-1461
74. A. Trichopoulou T. Costacou C. Bamia D. Trichopoulos Adherence to a Mediterranean diet and survival in a Greek population N Engl J Med 348 2003 2599-2608
75. E.R. Mohler 3rd W.R. Hiatt M.A. Creager Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease Circulation 108 2003 1481-1486
76. Hooper L, Summerbell CD, Higgins JP et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev 2001;(3):CD002137.
77. M. Higgins W. Kannel R. Garrison J. Pinsky J. Stokes III Hazards of obesity-the Framingham experience Acta Med Scand Suppl 723 1988 23-36
78. A. Planas A. Clara J.M. Pou et al. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men Int J Obes Relat Metab Disord 25 2001 1068-1070
79. J.T. Powell P.J. Franks N.R. Poulter Does nibbling or grazing protect the peripheral arteries from atherosclerosis? J Cardiovasc Risk 6 1999 19-22
80. A.M. Dattilo P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis Am J Clin Nutr 56 1992 320-328
81. M.G. Wyatt P.M. Scott D.J. Scott K. Poskitt R.N. Baird M. Horrocks Effect of weight on claudication distance Br J Surg 78 1991 1386-1388
82. P.T. Donnan M. Thomson F.G. Fowkes R.J. Prescott E. Housley Diet as a risk factor for peripheral arterial disease in the general population: the Edinburgh artery study Am J Clin Nutr 57 1993 917-921
83. A.T. Merchant F.B. Hu D. Spiegelman W.C. Willett E.B. Rimm A. Ascherio The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related J Nutr 133 2003 2863-2867
84. H.C. Hung A. Merchant W. Willett et al. The association between fruit and vegetable consumption and peripheral arterial disease Epidemiology 14 2003 659-665
85. M.R. Law C.D. Frost N.J. Wald By how much does dietary salt reduction lower blood pressure? I-Analysis of observational data among populations Br Med J 302 1991 811-815
86. J.A. Cutler D. Follmann P. Elliott I. Suh An overview of randomized trials of sodium reduction and blood pressure Hypertension 17 Suppl 1 1991 I27-I33
87. M. Brahimi B.I. Levy M.E. Safar H. Dabire Factors determining cardiac hypertrophy in hypertensive patients with or without peripheral vascular disease Clin Sci (Lond) 95 1998 261-267
88. S.J. Smith N.D. Markandu G.A. Sagnella G.A. MacGregor Moderate potassium chloride supplementation in essential hypertension: Is it additive to moderate sodium restriction? Br Med J (Clin Res Ed) 290 1985 110-113
89. B.M. Margetts L.J. Beilin R. Vandongen B.K. Armstrong Vegetarian diet in mild hypertension: A randomised controlled trial Br Med J (Clin Res Ed) 293 1986 1468-1471
90. I.L. Rouse L.J. Beilin B.K. Armstrong R. Vandongen Blood-pressure-lowering effect of a vegetarian diet: Controlled trial in normotensive subjects Lancet 1 1983 5-10
91. M. Langlois D. De Bacquer D. Duprez M. De Buyzere J. Delanghe V. Blaton Serum uric acid in hypertensive patients with and without peripheral arterial disease Atherosclerosis 168 2003 163-168
92. W.B. Kannel D.L. McGee Diabetes and cardiovascular disease. The Framingham study JAMA 241 1979 2035-2038
93. J.M. Murabito R.B. D'Agostino H. Silbershatz W.F. Wilson Intermittent claudication. A risk profile from the Framingham heart study Circulation 96 1997 44-49
94. T. Gordon W.B. Kannel Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study JAMA 221 1972 661-666
95. A.I. Adler R.J. Stevens A. Neil I.M. Stratton A.J. Boulton R.R. Holman UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes Diabetes Care 25 2002 894-899
96. G.M. Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595-1607
97. N.C. Dolan K. Liu M.H. Criqui et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning Diabetes Care 25 2002 113-120
98. M.D. McDaniel J.L. Cronenwett Basic data related to the natural history of intermittent claudication Ann Vasc Surg 3 1989 273-277
99. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837-853
100. R. Vliegenthart J.M. Geleijnse A. Hofman et al. Alcohol consumption and risk of peripheral arterial disease: The Rotterdam study Am J Epidemiol 155 2002 332-338
101. M.G. Marmot P. Elliott M.J. Shipley et al. Alcohol and blood pressure: the INTERSALT study Br Med J 308 1994 1263-1267
102. A.L. Klatsky G.D. Friedman A.B. Siegelaub M.J. Gerard Alcohol consumption and blood pressure Kaiser-Permanente multiphasic health examination data N Engl J Med 296 1977 1194-1200
103. J.I. Spark J.M. Robinson L. Gallavin et al. Patients with chronic critical limb ischaemia have reduced total antioxidant capacity and impaired nutritional status Eur J Vasc Endovasc Surg 24 2002 535-539
104. A. Silvestro F. Scopacasa G. Oliva T. de Cristofaro L. Iuliano G. Brevetti Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication Atherosclerosis 165 2002 277-283
105. K. Klipstein-Grobusch J.H. den Breeijen D.E. Grobbee H. Boeing A. Hofman J.C. Witteman Dietary antioxidants and peripheral arterial disease: The Rotterdam study Am J Epidemiol 154 2001 145-149
106. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000;(2);CD000987.
107. S. Yusuf G. Dagenais J. Pogue J. Bosch P. Sleight Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators N Engl J Med 342 2000 154-160
108. M. van den Berg G.H. Boers Homocystinuria: What about mild hyperhomocysteinaemia? Postgrad Med J 72 1996 513-518
109. I.C. Currie Y.G. Wilson J. Scott et al. Homocysteine: An independent risk factor for the failure of vascular intervention Br J Surg 83 1996 1238-1241
110. C.J. Boushey S.A. Beresford G.S. Omenn A.G. Motulsky A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes JAMA 274 1995 1049-1057
111. M.A. van den Bosch D.G. Bloemenkamp W.P. Mali et al. Hyperhomocysteinemia and risk for peripheral arterial occlusive disease in young women J Vasc Surg 38 2003 772-778
112. G. Wu C.J. Meininger Arginine nutrition and cardiovascular function J Nutr 130 2000 2626-2629
113. A. Tenenbaum E.Z. Fisman M. Motro L -Arginine: Rediscovery in progress Cardiology 90 1998 153-159
114. R.H. Boger S.M. Bode-Boger W. Thiele A. Creutzig K. Alexander J.C. Frolich Restoring vascular nitric oxide formation by l -arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease J Am Coll Cardiol 32 1998 1336-1344
115. A.J. Maxwell B.E. Anderson J.P. Cooke Nutritional therapy for peripheral arterial disease: A double-blind, placebo-controlled, randomized trial of HeartBar Vasc Med 5 2000 11-19
116. R.O. Gans H.J. Bilo E.G. et al. Weersink Fish oil supplementation in patients with stable claudication Am J Surg 160 1990 490-495
117. C. Ramirez-Tortosa J.M. Lopez-Pedrosa A. Suarez E. Ros J. Mataix A. Gil Olive oil- and fish oil-enriched diets modify plasma lipids and susceptibility of LDL to oxidative modification in free-living male patients with peripheral vascular disease: The Spanish nutrition study Br J Nutr 82 1999 31-39
118. T. Sommerfield W. Hiatt Omega-3 fatty acids for intermittent claudication Cochrane Database Syst Rev 3 2004 CD003833
119. A randomised blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996: 348; 1329-1339.
120. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Br Med J 324 2002 71-86